康泰医学
(300869)
| 流通市值：29.12亿 | | | 总市值：44.36亿 |
| 流通股本：2.64亿 | | | 总股本：4.02亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 225,877,603.09 | 100,279,216.75 | 468,004,884.41 | 343,992,692.71 |
| 营业总成本 | 255,161,799.97 | 114,012,396.72 | 496,009,962.87 | 335,255,538.73 |
| 其他经营收益 | | | | |
| 营业利润 | -51,222,992.64 | -8,832,683.51 | -26,332,877.65 | 10,077,737.15 |
| 利润总额 | -50,614,586 | -8,711,406.84 | -26,885,939.41 | 10,110,924.14 |
| 净利润 | -49,267,983.28 | -8,241,769.96 | -24,423,861.05 | 9,399,842.4 |
| 每股收益 | | | | |
| 其他综合收益 | -1,472,891.17 | -806,737.63 | -625,845.49 | -245,172.4 |
| 综合收益总额 | -50,740,874.45 | -9,048,507.59 | -25,049,706.54 | 9,154,670 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 2,217,124,908.32 | 2,369,024,751.22 | 2,343,751,054.89 | 2,375,515,002.32 |
| 非流动资产: | | | | |
| 非流动资产合计 | 421,658,045.97 | 425,337,879.64 | 427,441,144.35 | 415,370,465.55 |
| 资产总计 | 2,638,782,954.29 | 2,794,362,630.86 | 2,771,192,199.24 | 2,790,885,467.87 |
| 流动负债: | | | | |
| 流动负债合计 | 181,510,388.36 | 303,818,806.5 | 279,496,188.04 | 275,351,390.8 |
| 非流动负债: | | | | |
| 非流动负债合计 | 774,838,555.66 | 766,438,880.62 | 758,546,399.26 | 749,408,108.5 |
| 负债合计 | 956,348,944.02 | 1,070,257,687.12 | 1,038,042,587.3 | 1,024,759,499.3 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,682,434,010.27 | 1,724,104,943.74 | 1,733,149,611.94 | 1,766,125,968.57 |
| 股东权益合计 | 1,682,434,010.27 | 1,724,104,943.74 | 1,733,149,611.94 | 1,766,125,968.57 |
| 负债和股东权益合计 | 2,638,782,954.29 | 2,794,362,630.86 | 2,771,192,199.24 | 2,790,885,467.87 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 266,459,564.58 | 131,965,584.72 | 522,290,346.6 | 388,456,251.48 |
| 经营活动现金流出小计 | 233,019,698.96 | 105,338,310.05 | 500,002,903.28 | 368,855,357.91 |
| 经营活动产生的现金流量净额 | 33,439,865.62 | 26,627,274.67 | 22,287,443.32 | 19,600,893.57 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 2,142,636,433.57 | 836,484,694.58 | 4,079,616,112.18 | 2,984,983,164.09 |
| 投资活动现金流出小计 | 1,931,553,238.58 | 798,803,385.64 | 3,851,827,469.18 | 2,950,777,653.04 |
| 投资活动产生的现金流量净额 | 211,083,194.99 | 37,681,308.94 | 227,788,643 | 34,205,511.05 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 25,000,000 | 25,000,000 | 297,058,194.44 | 249,010,000 |
| 筹资活动现金流出小计 | 160,477,998.28 | 17,405,212.72 | 233,537,566.44 | 202,272,574.9 |
| 筹资活动产生的现金流量净额 | -135,477,998.28 | 7,594,787.28 | 63,520,628 | 46,737,425.1 |
| 汇率变动对现金及现金等价物的影响 | -27,328,087.9 | -13,346,067.85 | -15,181,674.71 | -6,992,635.8 |
| 现金及现金等价物净增加额 | 81,716,974.43 | 58,557,303.04 | 298,415,039.61 | 93,551,193.92 |
| 期末现金及现金等价物余额 | 1,064,439,785.52 | 1,041,280,114.13 | 982,722,811.09 | 777,858,965.4 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 81,716,974.43 | - | 298,415,039.61 | - |